← Back to Search

Brief Intervention for Substance Abuse in Transgender Women (TRUST Trial)

N/A

Waitlist Available

Research Sponsored by University of Central Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

HIV uninfected

Be older than 18 years old

Must not have

HIV infected transgender woman

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to use a brief intervention to reduce substance abuse in at-risk transgender women in Florida, in order to increase prevention methods for HIV.

Who is the study for?

This trial is for transgender women over the age of 18 living in South Florida who are not currently using substances as per AUDIT and SBIRT criteria, and are HIV negative. It's not open to those with hazardous alcohol or drug use or transgender women who are HIV positive.

What is being tested?

The study tests an adapted brief intervention called SBIRT-T designed specifically for at-risk transgender women to prevent substance abuse and promote HIV prevention strategies like routine screening, PrEP, and nPEP uptake.

What are the potential side effects?

Since this trial involves a behavioral intervention rather than medication, traditional side effects aren't expected. However, participants may experience emotional discomfort discussing sensitive topics during the sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have HIV.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am a transgender woman living with HIV.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of participants with substance abuse

Secondary study objectives

Rate of Preexposure prophylaxis (PrEP) election

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: SBIRT-TExperimental Treatment1 Intervention

The screening, brief intervention and referral to treatment (SBIRT-T) will be adapted and used as the intervention in the experimental arm

Group II: INFO-CActive Control1 Intervention

The INFO-C group is a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT-T format via printed and audio-visual study material

0 / 2Eligibility criteria met